University of Texas Health Science Center at San Antonio, Division of Diabetes, Department of Medicine, Texas, USA.
Expert Opin Investig Drugs. 2011 Dec;20(12):1717-22. doi: 10.1517/13543784.2011.630660. Epub 2011 Oct 24.
Obesity is a major health threat in the Western world because of its high incidence and prevalence, and its association with metabolic and cardiovascular disease as well as cancer. The reduction of food intake in obese patients can be achieved only transiently (generally for no longer than 6 months), in the absence of concomitant pharmacological therapy. Only bariatric surgery provides a means to increase satiety and/or decrease nutrient absorption in obese patients, in the long term.
This article reviews the available pharmacological treatments for obesity as well as the pharmacology and mechanism of action of exenatide in obese type 2 diabetic patients.
Exenatide is a potential new candidate treatment for obesity, possibly in combination with other hormones that increase satiety (leptin) and slow gastric emptying (amylin).
肥胖是西方世界的一个主要健康威胁，因为它的发病率和患病率都很高，而且它与代谢和心血管疾病以及癌症有关。在没有伴随药物治疗的情况下，肥胖患者的食物摄入量只能暂时减少（通常不超过 6 个月）。只有减肥手术才能为肥胖患者提供一种长期增加饱腹感和/或减少营养吸收的方法。
本文综述了目前用于肥胖症的药物治疗方法，以及 exenatide 在肥胖 2 型糖尿病患者中的药理学和作用机制。
Exenatide 可能是肥胖症的一种新的潜在候选治疗方法，可能与其他增加饱腹感（瘦素）和减缓胃排空（胰淀素）的激素联合使用。
